Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases

Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) for the treatment of two rare kidney diseases in adult and adolescent patients: C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The treatments have been approved for administration in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor […] The post Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases appeared first on Pharmafile.

Continue reading →